GOLDMAN SACHS GROUP INC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$6,443,721
-73.2%
313,106
-38.8%
0.00%
-80.0%
Q2 2023$24,072,594
-39.4%
511,965
-45.9%
0.01%
-37.5%
Q1 2023$39,699,951
+10.0%
946,138
+0.0%
0.01%0.0%
Q4 2022$36,084,864
-17.1%
946,116
-14.9%
0.01%
-20.0%
Q3 2022$43,527,000
+21.8%
1,111,522
+0.5%
0.01%
+25.0%
Q2 2022$35,733,000
+244.4%
1,106,276
+252.9%
0.01%
+300.0%
Q1 2022$10,376,000
-46.1%
313,457
-30.8%
0.00%
-50.0%
Q4 2021$19,268,000
-8.0%
452,959
-4.1%
0.00%0.0%
Q3 2021$20,936,000
-27.4%
472,494
-6.9%
0.00%
-33.3%
Q2 2021$28,831,000
-19.2%
507,506
+6.4%
0.01%
-33.3%
Q1 2021$35,697,000
-38.0%
476,907
-28.4%
0.01%
-40.0%
Q4 2020$57,603,000
+76.7%
665,860
+24.9%
0.02%
+66.7%
Q3 2020$32,591,000
-3.6%
533,235
-34.4%
0.01%
-10.0%
Q2 2020$33,795,000
+41.6%
812,785
-2.2%
0.01%
+11.1%
Q1 2020$23,871,000
-37.0%
831,188
+58.3%
0.01%0.0%
Q4 2019$37,906,000
-18.3%
525,092
+58.9%
0.01%
-30.8%
Q3 2019$46,374,000
-25.5%
330,558
-2.8%
0.01%
-27.8%
Q2 2019$62,252,000
+19.7%
340,006
+4.0%
0.02%
+12.5%
Q1 2019$52,020,000
+103.5%
327,064
+22.6%
0.02%
+100.0%
Q4 2018$25,557,000
-19.3%
266,804
+19.0%
0.01%0.0%
Q3 2018$31,660,000
-52.2%
224,143
-47.0%
0.01%
-55.6%
Q2 2018$66,199,000
+26.6%
422,915
+30.2%
0.02%
+38.5%
Q1 2018$52,301,000
-4.3%
324,709
-2.1%
0.01%0.0%
Q4 2017$54,637,000
+58.0%
331,719
-40.2%
0.01%
+44.4%
Q3 2017$34,581,000
-60.9%
555,078
-50.0%
0.01%
-60.9%
Q2 2017$88,435,000
+668.7%
1,110,430
+586.0%
0.02%
+666.7%
Q1 2017$11,504,000
+46.4%
161,867
+5.2%
0.00%
+50.0%
Q4 2016$7,859,000
-45.2%
153,927
-50.6%
0.00%
-50.0%
Q3 2016$14,343,000
+66.7%
311,480
+9.1%
0.00%
+100.0%
Q2 2016$8,604,000
+107.5%
285,581
+120.8%
0.00%0.0%
Q1 2016$4,146,000
-60.9%
129,324
-28.9%
0.00%
-50.0%
Q4 2015$10,605,000
+65.3%
181,911
+20.0%
0.00%
+300.0%
Q3 2015$6,415,000
+160.1%
151,582
+348.7%
0.00%0.0%
Q2 2015$2,466,000
+949.4%
33,779
+621.6%
0.00%
Q1 2015$235,000
-81.1%
4,681
-86.3%
0.00%
Q4 2014$1,246,000
-31.9%
34,054
-41.4%
0.00%
-100.0%
Q3 2014$1,831,00058,1360.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Integral Health Asset Management, LLC 311,000$10,294,0002.68%
Palo Alto Investors LP 851,719$28,192,0002.18%
Boxer Capital, LLC 1,094,000$36,211,0001.86%
DAFNA Capital Management LLC 180,306$5,968,0001.56%
Deep Track Capital, LP 675,000$22,343,0001.43%
Bellevue Group AG 3,052,404$101,034,0001.17%
Ikarian Capital, LLC 249,907$8,272,0001.09%
Ikarian Capital, LLC 250,000$8,275,0001.09%
Artal Group S.A. 750,000$24,825,0001.04%
SECTOR GAMMA AS 118,476$3,922,0000.85%
View complete list of SAGE THERAPEUTICS INC shareholders